Sign up online today & collaborate
or click here to find out more
New report calling for the Biomedical Catalyst scheme to be continued in the interest of the nation’s health and wealth.
Today the UK BioIndustry Association (BIA) publishes a new report, The Biomedical Catalyst, making the case to continue.
Published following the announcement of the last round of the current Biomedical Catalyst (BMC) funding allocation, the report gives a retrospective of the current scheme and showcases ten case studies from companies who have been recipients of BMC funding.
To date the BMC scheme has awarded over £250 million to accelerate medical research. Over 180 business-led projects have been supported with funds worth over £130 million and with a total project value of over £240 million. This means that over £100m of additional private capital, in the form of matched funding, has been leveraged as a condition of the Biomedical Catalyst awards. Furthermore, beyond the Biomedical Catalyst awards, post-award funded companies and academics have realised in excess of a further billion pounds in the form of additional private finance, grant funding, via licensing or acquisition.
For more click here
Source: One nucleus